Silymarin Decreases Connective Tissue Growth Factor to Improve Liver Fibrosis in Rats Treated with Carbon Tetrachloride

Silymarin is an herbal product showing potential as protection against hepatic disorders. In an attempt to develop the agent for the treatment of hepatic fibrosis, we screened the effects of silymarin on a rat model of hepatic fibrosis induced by carbon tetrachloride (CCl4). Intraperitoneal administration of CCl4 to rats for 8weeks not only increased the plasma levels of glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) but also induced a marked increase in the formation of hepatic fibrosis. Moreover, the activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx) were also reduced in the liver of rats treated with CCl4. Oral administration of silymarin (200mg/kg, three times daily), in parallel, decreased the plasma levels of GOT and GPT. Furthermore, in addition to the improvement of hepatic fibrosis, the hepatic levels of hydroxyproline and connective tissue growth factor (CTGF) were both markedly decreased by silymarin. Silymarin also elevated the activities of SOD and GPx in liver isolated from CCl4-treated rats. The results suggest that oral administration of silymarin protects against CCl4-induced hepatic fibrosis in rats, likely due to the decrease in fibrotic parameters such as CTGF. Copyright (c) 2012 John Wiley & Sons, Ltd.